161 related articles for article (PubMed ID: 8733951)
1. Three new residual error models for population PK/PD analyses.
Karlsson MO; Beal SL; Sheiner LB
J Pharmacokinet Biopharm; 1995 Dec; 23(6):651-72. PubMed ID: 8733951
[TBL] [Abstract][Full Text] [Related]
2. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
3. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
Ette EI; Onyiah LC
Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
[TBL] [Abstract][Full Text] [Related]
4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
5. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
Silber HE; Kjellsson MC; Karlsson MO
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
[TBL] [Abstract][Full Text] [Related]
6. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
Yano Y; Beal SL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):171-92. PubMed ID: 11381569
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic parameter estimation: population size versus number of samples.
Girgis S; Pai SM; Girgis IG; Batra VK
AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
[TBL] [Abstract][Full Text] [Related]
8. The effect of collinearity on parameter estimates in nonlinear mixed effect models.
Bonate PL
Pharm Res; 1999 May; 16(5):709-17. PubMed ID: 10350015
[TBL] [Abstract][Full Text] [Related]
9. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.
Wählby U; Thomson AH; Milligan PA; Karlsson MO
Br J Clin Pharmacol; 2004 Oct; 58(4):367-77. PubMed ID: 15373929
[TBL] [Abstract][Full Text] [Related]
10. Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?
Laporte-Simitsidis S; Girard P; Mismetti P; Chabaud S; Decousus H; Boissel JP
J Pharm Sci; 2000 Feb; 89(2):155-67. PubMed ID: 10688745
[TBL] [Abstract][Full Text] [Related]
11. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
Knights J; Rohatagi S
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
[TBL] [Abstract][Full Text] [Related]
12. Analysis of errors in parameter estimation with application to physiological systems.
Grove TM; Bekey GA; Haywood LJ
Am J Physiol; 1980 Nov; 239(5):R390-400. PubMed ID: 7435652
[TBL] [Abstract][Full Text] [Related]
13. Analyzing multi-response data using forcing functions.
Zhang L; Sheiner LB
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):283-305. PubMed ID: 16283535
[TBL] [Abstract][Full Text] [Related]
14. Model-Based Residual Post-Processing for Residual Model Identification.
Ibrahim MMA; Nordgren R; Kjellsson MC; Karlsson MO
AAPS J; 2018 Jul; 20(5):81. PubMed ID: 29968184
[TBL] [Abstract][Full Text] [Related]
15. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
Mandema JW; Verotta D; Sheiner LB
J Pharmacokinet Biopharm; 1992 Oct; 20(5):511-28. PubMed ID: 1287200
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.
White DB; Walawander CA; Tung Y; Grasela TH
J Pharmacokinet Biopharm; 1991 Feb; 19(1):87-112. PubMed ID: 2023111
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
Proost JH; Schiere S; Eleveld DJ; Wierda JM
Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
[TBL] [Abstract][Full Text] [Related]
18. The importance of modeling interoccasion variability in population pharmacokinetic analyses.
Karlsson MO; Sheiner LB
J Pharmacokinet Biopharm; 1993 Dec; 21(6):735-50. PubMed ID: 8138894
[TBL] [Abstract][Full Text] [Related]
19. A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.
Dosne AG; Bergstrand M; Karlsson MO
J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):137-51. PubMed ID: 26679003
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
